Kedudukan dalam Saham
#2339
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Perubahan (1 tahun)
192.01%
Perdagangan Immunovant, Inc. (IMVT)
Harga IMVT dengan permodalan pasaran b
Modal pasaran bagi Immunovant, Inc.(IMVT)
Modal Pasaran: $8.97B
Sehingga August 2026, Immunovant, Inc. mempunyai modal pasaran sebanyak $8.97B. Ini menjadikan Immunovant, Inc. syarikat ke-2339th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Immunovant, Inc. dari 2019 hingga 2026
IMVT berbanding dengan 5 teratas yang paling popular stocks
| Harga IMVT |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.118T
|
+56,928.00%
|
|
|
|
|
$4.548T
|
+50,573.77%
|
|
|
|
|
$4.168T
|
+46,345.62%
|
|
|
|
|
$3.632T
|
+40,366.55%
|
|
|
|
|
$2.806T
|
+31,166.74%
|
